Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Enoxaparin Sodium Injection Obtains Drug Registration Certificate in Tajikistan.
Changshan Pharmaceutical (300255.SZ) released an announcement that the company recently received notification that the company's drug Enoxaparin Sodium Injection has obtained a drug registration certificate issued by the drug supervision department of Tajikistan.
Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced that the company has recently received notification that their drug Enoxaparin Sodium Injection has obtained a drug registration certificate issued by the Tajikistan drug regulatory authority.
Enoxaparin Sodium Injection is used to prevent venous thromboembolic diseases (prevention of intravenous blood clot formation), especially related to orthopedic or general surgery; treat established deep vein thrombosis, with or without pulmonary embolism, with mild clinical symptoms, excluding cases requiring surgical treatment or thrombolytic therapy for pulmonary embolism; used in combination with aspirin to treat unstable angina and non-Q wave myocardial infarction; and used in extracorporeal circulation during hemodialysis to prevent blood clotting.
Related Articles
Geely Auto (00175) spent HK$631,600 to repurchase 41,000 shares on March 6th.
SKYMISSION GP (01429): The offeror received valid acceptance for a total of 804,000 shares of the offer shares under the offer.
Vitasoy International (00345) spent 3.988 million Hong Kong dollars on March 6 to repurchase 572,000 shares.
Geely Auto (00175) spent HK$631,600 to repurchase 41,000 shares on March 6th.
SKYMISSION GP (01429): The offeror received valid acceptance for a total of 804,000 shares of the offer shares under the offer.
Vitasoy International (00345) spent 3.988 million Hong Kong dollars on March 6 to repurchase 572,000 shares.
RECOMMEND
